Rapid improvement of pyoderma gangrenosum after treatment with infliximab

Joanna L. Chan, Michael S. Graves, Clay J. Cockerell, Amit G. Pandya

Research output: Contribution to journalArticle

9 Scopus citations


Infliximab, a novel chimeric anti-tumor necrosis factor-α (TNF-α) monoclonal antibody, has been increasingly used in the treatment of pyoderma gangrenosum. However, an established dosing regimen is lacking in the published literature. A variety of dosing regimens have been suggested, including a treatment schedule similar to that of psoriasis. The authors report a case of rapid response to infliximab in a patient with pyoderma gangrenosum associated with inflammatory bowel disease utilizing a dosing regimen similar to that used for psoriasis.

Original languageEnglish (US)
Pages (from-to)702-704
Number of pages3
JournalJournal of Drugs in Dermatology
Issue number6
Publication statusPublished - Jun 2010


ASJC Scopus subject areas

  • Dermatology

Cite this

Chan, J. L., Graves, M. S., Cockerell, C. J., & Pandya, A. G. (2010). Rapid improvement of pyoderma gangrenosum after treatment with infliximab. Journal of Drugs in Dermatology, 9(6), 702-704.